Inhibitors of mutated IDH1/2 enzymes (Figure 2) entered clinical trials for targeted therapy of gliomas [81] and may represent an interesting opportunity also for patients with chondrosarcomas. The gene discussed is IDH1; the disease is chondrosarcoma.